Immunovant (NASDAQ: IMVT) CFO sells 6,798 shares to cover RSU taxes

Rhea-AI Filing Summary

Immunovant, Inc. Chief Financial Officer Tiago Girao reported the sale of 6,798 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share. The mandated “sell to cover” transaction funded tax withholding on 13,024 vested RSUs, leaving him with 240,798 shares held directly.

Insider Trade Summary

Net Seller: 6,798 shares

Net Sell 1 txn

Insider Girao Tiago

Role Chief Financial Officer

Sold 6,798 shs ($263K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	6,798	$38.69	$263K

Holdings After Transaction: Common Stock — 240,798 shares (Direct)

Footnotes (2)

1. F1. On May 1, 2025, the holder was granted 208,388 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on May 5, 2025, of which 13,024 of these RSUs vested on July 21, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Shares sold: 6,798 shares Weighted average sale price: $38.69 per share Post-transaction holdings: 240,798 shares +3 more

6 metrics

Shares sold 6,798 shares Common stock sold on July 23, 2026 in a sell-to-cover transaction

Weighted average sale price $38.69 per share Average price for the 6,798 shares sold on July 23, 2026

Post-transaction holdings 240,798 shares Common shares beneficially owned directly after the sale

RSU grant size 208,388 RSUs Restricted stock units granted on May 1, 2025

RSUs vested 13,024 RSUs Portion of the May 1, 2025 grant that vested on July 21, 2026

Sale price range $38.18–$39.05 per share Range of individual transaction prices for the 6,798 shares sold

Key Terms

restricted stock units ("RSUs"), sell to cover, weighted average price, tax withholding obligations

4 terms

restricted stock units ("RSUs") financial

"the holder was granted 208,388 restricted stock units ("RSUs"), as previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/24/2026 - 05:58 PM Accepted by SEC EDGAR 07/24/2026 - 05:57 PM Learn about SEC filing dates

FAQ

What insider transaction did Immunovant (IMVT) CFO Tiago Girao report?

Tiago Girao reported a sale of 6,798 shares of Immunovant common stock on July 23, 2026 at a weighted average price of $38.69 per share, according to his Form 4 insider trading report.

Why did the Immunovant (IMVT) CFO sell 6,798 shares?

The CFO’s 6,798-share sale was to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The company requires a “sell to cover” transaction for these taxes, so the sale was not a discretionary trade.

How many Immunovant (IMVT) shares does the CFO hold after this transaction?

After the reported sale, Tiago Girao beneficially owns 240,798 shares of Immunovant common stock directly. This figure comes from the post-transaction holding line in the Form 4 for the July 23, 2026 sell-to-cover transaction.

What RSU vesting triggered the Immunovant (IMVT) CFO’s tax-related sale?

The sale relates to a prior grant of 208,388 RSUs awarded on May 1, 2025. Of these, 13,024 RSUs vested on July 21, 2026, generating tax withholding obligations that were satisfied through the mandated sell-to-cover stock sale.

Was the Immunovant (IMVT) CFO’s Form 4 sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnote describes the sale as a mandated “sell to cover” for tax withholding, not as a discretionary trade executed under a Rule 10b5-1 trading plan.

At what prices were the Immunovant (IMVT) CFO’s shares sold?

The reported $38.69 price is a weighted average. According to the Form 4 footnote, the 6,798 shares were sold in multiple transactions at prices ranging from $38.18 to $39.05 per share, inclusive, on July 23, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girao Tiago

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		S		6,798(1)	D	$38.69(2)	240,798	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On May 1, 2025, the holder was granted 208,388 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on May 5, 2025, of which 13,024 of these RSUs vested on July 21, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)